Supriya Lifescience IPO
Supriya Lifescience IPO is listed on BSE and NSE, priced at ₹265–₹274 per share. The stock debuted at ₹421, delivering a listing gain of 53.6%. The IPO had a lot size of ₹54 shares and a minimum investment of ₹14,796.
Supriya Lifescience IPO
- IPO Dates
- Dec 16, 2021 – Dec 20, 2021
- Price band
- ₹265-274 per equity share
- Minimum Investment
- ₹14,796
- Issue size
- Total 700 Crores : Fresh Issue: ₹200 Cr + Offer for Sale : ₹500 Cr
- Lot size
- 54
- Allotment Date
- Dec 24, 2021
- Listing
- Dec 28, 2021
- Listing At
- BSE, NSE
IPO timeline
-
Dec 16, 2021
Open Date
Completed
-
Dec 20, 2021
Close Date
Completed
-
Dec 24, 2021
Allotment Date
Completed
-
Dec 28, 2021
Listing Date
Completed
Price Summary
- Last closing
- 689.80 (151.75%)
- 52 week high
- 832.40
- 52 week low
- 545.50
- Last update
Supriya Lifescience IPO Essentials
Supriya Lifescience IPO Details
Supriya Lifescience IPO is priced at ₹265-274 per share with a total issue size of Total 700 Crores : Fresh Issue: ₹200 Cr + Offer for Sale : ₹500 Cr. The IPO has a lot size of 54 shares and is listed on BSE and NSE.
- Issue price
- ₹265-274 per equity share
- Lot size
- 54 shares
- Face value
- ₹2 Per Equity Share
- Issue size
- Total 700 Crores : Fresh Issue: ₹200 Cr + Offer for Sale : ₹500 Cr
- Listing at
- BSE, NSE
- List price
- 421.00(NSE)
- Listing date
- Registrar
- Link Intime India Private Limited
- Lead manager
-
ICICI Securities Limited, and Axis Capital Limited
Supriya Lifescience IPO Analytics
Supriya Lifescience IPO category-wise subscription trends show day-wise participation across QIB, NII, and retail investors.
Supriya Lifescience IPO Subscription Status
Supriya Lifescience IPO subscription status shows demand across retail, NII, and QIB categories, helping investors understand overall participation trends.
The IPO subscription status indicates investor demand across categories.
| As on | QIB |
NII
|
Retail | Total |
|---|---|---|---|---|
| Shares Offered / Reserved | 76,64,232 |
38,32,116
|
25,54,745 | 140,51,093 |
|
Day 1
16-12-21 05:00 PM
|
0.00 x |
0.66x
|
11.84 x | 2.33 x |
|
Day 2
17-12-21 05:00 PM
|
0.53 x |
2.90x
|
25.37 x | 5.70 x |
|
Day 3
20-12-21 05:00 PM
|
31.83 x |
161.22x
|
55.75 x | 71.46 x |
|
Total No. of Applications
|
category wise applications | ||
|---|---|---|---|
| 2354306 (Approx) | 49.76 | ||
Supriya Lifescience Valuations
Earnings
- EPS (Post IPO)
- ₹15.39/-
- P/E Ratio
- 17.81
Returns
- RoNW
- 46.04%
Supriya Lifescience Financials( In Crs.)
| 31-Mar-21 | 31-Mar-20 | 31-Mar-19 | |
|---|---|---|---|
| Assets | 445.82 | 336.40 | 253.05 |
| Revenue | 396.22 | 322.71 | 285.86 |
| Profit After Tax | 123.82 | 73.37 | 39.42 |
Supriya Lifescience Company & Offer Insights
About Supriya Lifescience
Supriya Lifescience is engaged in the manufacturing of Active pharmaceutical ingredients (APIs). As of March 31, 2021, the company produces 38 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic. The company has been the largest exporter of Chlorpheniramine Maleate and Ketamine Hydrochloride from India between Fiscal 2017 and 2021. The company is also one of the largest exporters of Salbutamol Sulphate from India in FY 2021 in terms of volume.In Fiscal 2021, the company's products were exported to 86 countries to 1,296 customers including 346 distributors. The company has API business in Europe, Latin America, Asia, and North America.Supriya Lifescience has a modern manufacturing facility in Maharashtra spread across 23,806 sq. mts, having a reactor capacity of 547 KL/ day including 7 clean rooms. The company has also acquired a plot of land, admeasuring 12,551 sq. mt, near the present manufacturing facility, to expand its manufacturing infrastructure. The company's manufacturing facility has received approvals from USFDA, EDQM TGA-Australia, KFDA-Korea, PMDA Japan, NMPA (previously known as SFDA)- China, Health Canada, in relation to API products being exported to the relevant jurisdictions by the company.
Supriya Lifescience Promoter(s)
Satish Waman Wagh are the company's promoters of Supriya Lifescience.
Supriya Lifescience IPO Issue Objectives
- •
- Funding capital expenditure requirements of their Company
- •
- Repayment and/ or pre-payment, in full or part, of certain borrowings availed by their Company
- •
- General corporate purposes
Supriya Lifescience IPO - Anchor Investors
Supriya Lifescience mobilises Rs 315 crore from anchor investors ahead of IPO
Marquee investors who participated and invested in the company were Dovetail India Fund, Cohesion MK Best Ideas, Hornbill Orchid India Fund, Volrado Venture Partners Fund, Optimix Wholesale Global, and Societe Generale.
Among domestic investors, Nippon Life, Aditya Birla Sun Life Insurance, Abakkus Growth Fund, and Reliance General Insurance also put in money in Supriya Lifescience.
Supriya Lifescience IPO - Peers Comparison
| P/B Ratio | P/E Ratio | RoNW | Revenue(in Cr.) | |
|---|---|---|---|---|
| Supriya Lifescience | 5.99 | 17.81 | 46.04% | 396.22 |
| Solara Active Pharma | 2.48 | 20.33 | 12.22% | 1,645.29 |
| Neuland Lab | 2.75 | 30.26 | 9.07% | 953.01 |
| Aarti Drugs | 6.12 | 26.54 | 23.06% | 1,921.31 |
Contact Information
Frequently Asked Questions
Click any question to reveal the answer
Supriya Lifescience IPO is a book-built IPO worth ₹Total 700 Crores : Fresh Issue: ₹200 Cr + Offer for Sale : ₹500 Cr. The price band is ₹265–₹274 per share. The IPO opens on Dec 16, 2021 and closes on Dec 20, 2021. It will be listed on BSE and NSE. Link Intime India Private Limited is the registrar.
The price band of Supriya Lifescience IPO is ₹265 to ₹274 per share.
The lot size of Supriya Lifescience IPO is 54 shares.
The minimum investment for Supriya Lifescience IPO is approximately ₹14,796 based on the upper price band .
Supriya Lifescience IPO opens on Dec 16, 2021 and closes on Dec 20, 2021.
The allotment date of Supriya Lifescience IPO is Dec 24, 2021.
Supriya Lifescience IPO is expected to be listed on Dec 28, 2021, on BSE and NSE .
Supriya Lifescience IPO listed on Dec 28, 2021. It was issued at ₹421.00(NSE) and is currently around ₹689.80 as on 14-May-2026 3:30 PM, which is approximately 151.8% versus issue price. The 52-week high is ₹832.40.
Based on listing and post-listing performance, Supriya Lifescience IPO delivered around 151.8% over issue price. Whether it was worth applying depends on your risk profile, allocation, and holding horizon.
To buy Supriya Lifescience IPO shares after listing, log in to your broker app (such as Zerodha, Angel One, Groww, Upstox, ICICI Direct), search the stock symbol, place a delivery/CNC order, and confirm quantity and price.
Supriya Lifescience IPO valuation snapshot: P/E 17.81, EPS ₹15.39/-, P/B N/A, RoNW 46.04%, and market cap N/A.
To apply for Supriya Lifescience IPO, open the IPO Ji app or website, select the IPO, choose your demat account, enter the quantity, and submit the application.
You can check the live subscription status of Supriya Lifescience IPO on IPO Ji or stock exchange websites. It shows real-time demand across retail, NII, and QIB categories.
Pre-apply allows investors to submit their IPO application before the bidding period starts. The order is placed automatically when the IPO opens.
If you pre-apply for Supriya Lifescience IPO, your order will be placed when the IPO bidding starts, and a UPI mandate request will be generated.
You can check Supriya Lifescience IPO allotment status on the registrar or stock exchange websites using your PAN or application number after allotment. You can also check the Supriya Lifescience IPO allotment status on IPO Ji for quick and easy access.